Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Treasury Shares (2023 - 2025)

Avidity Biosciences (RNA) has disclosed Treasury Shares for 3 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares rose 43.2% year-over-year to $3.0 million, compared with a TTM value of $3.0 million through Dec 2025, up 43.2%, and an annual FY2025 reading of $3.0 million, up 43.2% over the prior year.
  • Treasury Shares was $3.0 million for Q4 2025 at Avidity Biosciences, up from $810000.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $3.0 million in Q4 2025 and bottomed at $607000.0 in Q1 2023.
  • Average Treasury Shares over 3 years is $1.3 million, with a median of $1.1 million recorded in 2024.
  • The sharpest move saw Treasury Shares surged 181.47% in 2024, then tumbled 42.76% in 2025.
  • Year by year, Treasury Shares stood at $750000.0 in 2023, then soared by 181.47% to $2.1 million in 2024, then soared by 43.2% to $3.0 million in 2025.
  • Business Quant data shows Treasury Shares for RNA at $3.0 million in Q4 2025, $810000.0 in Q1 2025, and $2.1 million in Q4 2024.